Russia said its Sputnik V vaccine is 92% effective at protecting
people from COVID-19, according to interim trial results.
Developers of the Sputnik
V Covid-19 vaccine said on Thursday that AstraZeneca should try combining
its experimental shot with the Russian one to boost efficacy.
Russia said its Sputnik V vaccine is 92% effective at protecting people from
Covid-19, according to interim trial results, while AstraZeneca said its
Covid-19 vaccine was 70% effective in pivotal trials and could be up to 90% effective.
"If they go
for a new clinical trial, we suggest trying a regimen of combining the AZ shot
with the #SputnikV human adenoviral vector shot to boost efficacy," the
developers of the Russian vaccine said on their Twitter account.
"Combining
vaccines may prove important for revaccinations." AstraZeneca has said it
will have as many as 200 million doses of its vaccine by the end of 2020.
The British
developed vaccine is viewed as offering one of the best hopes for many
developing countries because of its cheaper price and ability to be transported
at normal fridge temperatures.
With 2,187,990
infections, Russia has the fourth-largest number of Covid-19 cases in the world
behind the United States, India and Brazil.
AstraZeneca
is likely to run an additional global trial to assess the efficacy of its
vaccine, its chief executive Pascal Soriot was quoted as saying by Bloomberg
News, after questions were raised over the results from its late-stage study.
No comments:
Post a Comment